“Long-Term Upadacitinib Safety in Moderate-to-Severe Atopic Dermatitis up to 7 Years: An Integrated Analysis With Over 9600 Patient-Years of Exposure”. SKIN The Journal of Cutaneous Medicine 10, no. 2 (March 10, 2026): s727. Accessed April 17, 2026. https://skin.dermsquared.com/skin/article/view/4035.